Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Computed tomography quantification of body adiposity and induction outcomes in patients with newly diagnosed acute lymphoblastic leukemia

Jose Tinajero, Hoda Pourhassan, Chandana Lall, Dat Ngo, Vaibhav Agrawal, Paul Koller, Lindsey Murphy, Shukaib Arslan, Yazeed Samara, Amandeep Salhotra, Stephen Forman, Guido Marcucci, Anthony Selwyn Stein, Ibrahim Aldoss, Vinod Pullarkat

Blood (2025) 146 (Supplement 1): 6829.

https://doi.org/10.1182/blood-2025-6829

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Amandeep Salhotra, Jamie Wagner, Dongyun Yang, Haris Ali, Salman Otoukesh, Jemily Juan, Sindhu Saraswathy, Isaac Garcia, Dileshni Tilakawardane, Sunmin Park, Stephen Forman, Ryotaro Nakamura, Christine Brown, Enrique Montero

Blood (2025) 146 (Supplement 1): 276.

https://doi.org/10.1182/blood-2025-276

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Monzr M. Al Malki, Susanta Hui, Dongyun Yang, Sally Mokhtari, Hoda Pourhassan, Matthew Mei, Amanda Blackmon, Firoozeh Sahebi, Amandeep Salhotra, Brian Ball, Shukaib Arslan, Salman Otoukesh, Haris Ali, Guido Marcucci, Ryotaro Nakamura, Stephen Forman, Anthony Selwyn Stein, Jeffrey Wong

Blood (2025) 146 (Supplement 1): 376.

https://doi.org/10.1182/blood-2025-376

Published: 2025

Journal Articles

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Paul Koller, Jose Tinajero, Dat Ngo, Dongyun Yang, Ahmed Aribi, Ibrahim Aldoss, Vinod Pullarkat, Amandeep Salhotra, Eileen Smith, Anthony Selwyn Stein, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Monzr M. Al Malki

Blood (2025) 146 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2025-3411

Published: 2025

Journal Articles

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

Salman Otoukesh, Brian Ball, Dongyun Yang, Ketevan Gendzekhadze, Karamjeet Sandhu, Shukaib Arslan, Amanda Blackmon, Pamela Becker, Firoozeh Sahebi, Anna Pawlowska, Monzr M. Al Malki, Michelle Afkhami, Stephen Forman, Guido Marcucci, Vinod Pullarkat, Raju Pillai, Ryotaro Nakamura

Blood (2025) 146 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2025-1431

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Blood (2025) 146 (Supplement 1): 2516.

https://doi.org/10.1182/blood-2025-2516

Published: 2025

Journal Articles

Chronic myeloid leukemia (CML) evolution is not encoded in single-cell microstates, but emerges from population-level macrostates

David Frankhouser, Dandan Zhao, Yu-Hsuan Fu, Anupam Dey, Ziang Chen, Jihyun Irizarry, Jennifer Rangel Ambriz, Sergio Branciamore, Denis O'Meally, Jeffrey Trent, Stephen Forman, Ya-Huei Kuo, Adam MacLean, Bin Zhang, Russell Rockne, Guido Marcucci

Blood (2025) 146 (Supplement 1): 5026.

https://doi.org/10.1182/blood-2025-5026

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Elizabeth Budde, Marissa Del Real, John Baird, Lu Chen, Joo Song, Xiuli Wang, Swetha Thiruvengadam, Marie Hu, Alan Macias, Emanuela Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Stephen Forman, Larry Kwak

Blood (2025) 146 (Supplement 1): 268.

https://doi.org/10.1182/blood-2025-268

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

Monzr M. Al Malki, Dongyun Yang, Sally Mokhtari, Anissa Bailey, Pooja Rajeevan, Rhiannon Imbeah, Salman Otoukesh, Brian Ball, Paul Koller, Vaibhav Agrawal, Yazeed Samara, Firoozeh Sahebi, Ibrahim Aldoss, Andrew Artz, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Haris Ali

Blood (2025) 146 (Supplement 1): 2455.

https://doi.org/10.1182/blood-2025-2455

Published: 2025

Journal Articles

Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma

Ryan Urak, Alexandra Wolfarth, Donghoon Choi, Stephen Forman, Xiuli Wang

Blood (2025) 146 (Supplement 1): 5878.

https://doi.org/10.1182/blood-2025-5878

Published: 2025

Journal Articles

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood (2025) 146 (Supplement 1): 508.

https://doi.org/10.1182/blood-2025-508

Published: 2025

Journal Articles

Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia

Kaito Harada, Dandan Zhao, Miso Park, Fang Chen, Yongfang Xu, Yi Zhang, Yile Zhou, Bea Parcutela, Yead Jewel, Ashlie Munoz, Idoroenyi Amanam, Le Xuan Truong Nguyen, Jianjun Chen, Lucy Ghoda, Stephen Forman, John Williams, Bin Zhang, Guido Marcucci

Blood (2025) 146 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2025-2340

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

Blood (2025) 146 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2025-2441

Published: 2025

Journal Articles

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood (2025) 146 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2025-1684

Published: 2025

Journal Articles

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

Lindsey Murphy, Molly Thornock, Xinyi Du, Alysia Bosworth, Lanie Lindenfeld, Matthew Mei, Leslie Popplewell, Nicole Karras, Anna Pawlowska, Alex Herrera, F. Wong, Stephen Forman, Elizabeth Budde, Saro Armenian

Blood (2025) 146 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2025-1013

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Ibrahim Aldoss, Xiuli Wang, Lu Chen, Joo Song, Karamjeet Sandhu, Alan Macias, Neguine Sanani, Baishakhi Barva, Min Guan, Ruby Espinosa, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Guido Marcucci, Elizabeth Budde, Larry Kwak, Stephen Forman

Blood (2025) 146 (Supplement 1): 813.

https://doi.org/10.1182/blood-2025-813

Published: 2025

Journal Articles

Novel CTLA-4 costimulatory domain mitigates cytokine-related toxicity, improving the anti-cancer therapeutic index of CS1-CAR T cells for multiple myeloma

Xiuli Wang, Huifei Zheng, Sindhu Saraswathy, Jemily Juan, Isaac Garcia, Mary Clark, Stephen Forman, Enrique Montero

Blood (2025) 146 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2025-4110

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Computed tomography quantification of body adiposity and induction outcomes in patients with newly diagnosed acute lymphoblastic leukemia

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Chronic myeloid leukemia (CML) evolution is not encoded in single-cell microstates, but emerges from population-level macrostates

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Novel CTLA-4 costimulatory domain mitigates cytokine-related toxicity, improving the anti-cancer therapeutic index of CS1-CAR T cells for multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only